Invited review. Cholinesterase inhibitors for Alzheimer's disease therapy: From tacrine to future applications

Neurochemistry International

Volumn 32, Issue 5-6, 1998, Pages 413-419

  Giacobini, Ezio ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; HEPTYLSTIGMINE TARTRATE; METRIFONATE; PHYSOSTIGMINE; RIVASTIGMINE; TACRINE;

ALZHEIMER DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; GERIATRICS; HUMANS; TACRINE;

EID: 0032078728     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-0186(97)00124-1     Document Type: Review

References (41)

1. Albin, S.M., Bunegin, B., Massopust, L.C., Jannetta P., 1974. Ketamine-induced postanesthetic delirium attenuated by tetrahydroaminoacridine. Exp. Neurol. 44, 126-129.
2. Amberla, K., Nordberg, A., Viitanen, M., Winblad B., 1993. Long-term treatment with tacrine (THA) in Alzheimer disease evaluation of neuropsychological data. Acta. Neurol. Scand (Suppl. 149), 55-57
3. Anand, R., Hartman, R.D., Hayes, P.E., 1996. An overview of the development of SDZ ENA 713, a brain selective cholinesterase inhibitor. In Becker, R., Giacobini, E. (Eds), Alzheimer Disease: From Molecular Biology to Therapy. Birkhäuser, Boston, pp. 239-243.
4. Becker, R., Colliver, J., Elbe, R., 1990. Effects of Metrifonate, a long-acting cholinesterase inhibitor. Drug Devel. Res. 19, 425-434.
5. Becker, R., Moriearty, P., Unni, L., 1991. The second generation of cholinesterase inhibitors: Clinical and pharmacological effects. In Becker, R., Giacobini, E. (Eds), Cholinergic Basis for Alzheimer Therapy. Birkhäuser, Boston, pp. 263-296.
6. Becker, R., Colliver, J.A., Markwell, S.J., Moriearty, P., Unni, L.K., Vicari S., 1996a. Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer disease. Alz. Dis. and Assoc. Dis. 10, 124-131.
7. Becker, R., Moriearty, P., Unni, L., Vicari, S., 1996b.Cholinesterase inhibitors as therapy in Alzheimer's disease: benefit to risk considerations in clinical application. In Becker, R., Giacobini, E. (Eds), Alzheimer Disease: From Molecular Biology to Therapy. Birkhäuser, Boston, pp. 257-266.
8. Canal, I., Imbimbo, B.P., 1996. Clinical trials and therapeutics: Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease. Clin. Pharm. Therap. 15(12), 49-59
9. Davis, K.L., Mohs, R.S., 1982. Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine. Am. J. Psychiatry. 139, 1421-1424.
10. Eagger, S., Richards, M., Levy R., 1994. Long-term effects of tacrine in Alzheimers's disease: an open study. Intern. J. Ger. Psych. 9, 643-647.
11. Farlow, M., Gracon, S.I., Hershey, L.A., Lewis, K.W., Sadowski, C.H., Dolan-Ureno, J.A., 1992. Controlled trial of tacrine in Alzheimer's disease. J. Am. Med. Ass. 268, 2523-2529.
12. Giacobini, E., 1990. The cholinergic system in Alzheimer disease. In Aquilonius, S.-M., Gillberg, P,-G. (Eds), Cholinergic transmission: functional and clinical aspects. Elsevier, Amsterdam, Prog. in Brain Res. 84, 321-332.
13. Giacobini, E., 1994. Cholinomimetic therapy of Alzheimer's disease: does it slow down deterioration? In Racagni, G., Brunello, N., Langer, S.Z. (Eds), Recent Advances in the Treatment of Neurodegenerative Disorders and Cognitive Dysfunction International Academy of Biomedical Drug Research. Karger, New York, pp. 51-57.
14. Giacobini, E., 1995. Cholinesterase inhibitors: From preclinical studies to clinical efficacy in Alzheimer's disease. In Quinn, D., Balasubramaniam, A.S., Doctor, B.P., Taylor, P. (Eds), Enzymes of the Cholinesterase Family. Plenum Press, New York, pp. 463-469.
15. Giacobini, E., 1996. Cholinesterase inhibitors do more than inhibit cholinesterase. In Becker, R., Giacobini, E. (Eds), Alzheimer's Disease: From Molecular Biology to Therapy. Birkhäuser, Boston, pp. 187-204.
16. Giacobini, E., Becker, R., McIlhany, M., Kumar, V., 1988. Interacerebroventricular administration of cholinergic drugs: preclinical trials and clinical experience in Alzheimer patients. In Giacobini, E., Becker, R. (Eds), Current Research in Alzheimer Therapy. Taylor and Francis, New York, pp. 113-122.
17. Giacobini, E., Cuadra, G., 1994. Second and third generation cholinesterase inhibitors: From preclinical studies to clinical efficacy. In Giacobini, E., Becker, R. (Eds), Alzheimer Disease: Therapeutic Strategies. Birkhafadi]user, Boston, pp. 155-171.
18. Giacobini, E., DeSarno, P., Clark, B., McIlhany, M., 1989. The cholinergic receptor system of the human brain - Neurochemical and pharmacological aspects in aging and Alzheimer. In Nordberg, A., Fuxe, K., Holmstedt, B. (Eds), Prog. in Brain Res. Elsevier, Amsterdam, pp. 335-343.
19. Gordh, T., Walin, A., 1961. Potentiation of the neuromuscular effect of succinylcholine by tetrahydro-aminoacridine. Acta Anaesth. Scand. 5, 55-61.
20. Heilbronn, E. 1961. Inhibition of Cholinesterase by tetrahydroaminoacrin. Acta Chem. Scand. 15, 1386-1390.
21. Imbimbo, B.P., 1996. Eptastigmine: A cholinergic approach to the treatment of Alzheimer's disease. In Becker, R., Giacobini, E. (Eds), Alzheimer Disease: From Molecular Biology to Therapy. Birkhäuser, Boston, pp. 223-230.
22. Imbimbo, B.P., Lucchelli, P.E., 1994. A pharmacodynamic strategy to optimize the clinical response to eptastigmine. In Becker, R., Giacobini, E. (Eds), Alzheimer Disease: Therapeutic Strategies. Birkhäuser, Boston, pp. 223-230.
23. Imbimbo, B.P., Perini, M. Verdelli, G., Troetel W.M., 1997. XVth World Congress of Neurology, Buenos Aires. Sept. 1997. Abstr. 125.
24. Knapp, S. Wardlow, M.L. Albert, W., Wazters. D., Thal, J., 1991. Correlation between plasma physostigmine concentrations and percentage of acetylcholinesterase inhibition over time after controlled release of physostigmine in volunteer subjects. Drug Metab. Disp. 19(2), 400-404.
25. Knapp, M.J., Knopman, D.S., Solomon, P.R., 1994. A 30 week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. J. Am. Med. Ass. 271, 985-991.
26. Knopman, D., Schneider, L., Davis, K., 1996. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality. Neurol. 47, 166-177.
27. Mattio, T., McIlhany, M., Giacobini, E., Hallak, M., 1986. The effects of physostigmine on acetylcholinesterase activity of CSF, plasma and brain. A comparison of intravenous and intraventricular administration in beagle dogs. Neuropharm. 25, 1167-1177.
28. Mori, F., Lai, C.C., Fusi, F., Giacobini, E., 1995. Cholinesterase inhibitors increase secretion of APPs in rat brain cortex. Neuro Rep. 6(4), 633-636.
29. Morris, J. Cyrus, P. Orazem, J., Mas, J. Bieber, F., Gulanski, B., 1997. Metrifonate: potential therapy for Alzheimer's Disease. Amer. Soc. Neurol. Meeting (Boston, U.S.A.) Abstr. 155.
30. Roger, S.L., Friedhoff, T., 1996. The efficacy and safety of Donepezil in patients with Alzheimer's disease: Results of a U.S. multicentre, randomized, double-blind, placebo-controlled trial. Dementia 7, 293-300.
31. Roger, S.L., Doody, R., Mohs, R., Friedhoff, L.T., 1996. E2020 produces both clinical global and cognitive test improvement. Neurology 46, Abstr. 217.
32. Rupniak, N.M.J., Field, M.J., Samson, N.A., Steventon, M.J., Iversen, S.D., 1990. Direct comparison of cognitive facilitation by physostigmine and tetrahydroaminoacridine in two primate models. Neurobiol. of Aging 11, 609-613.
33. Scali, C., Giovannini, M.G., Bartolini, L., Prosperi, C., Hinz, V., Schmidt, B., Pepeu, G., 1997. Effect of metrifonate on extracellular brain acetylcholine and object recognition in aged rats. Eur. J. Pharmacology 325, 173-180.
34. Shaw, H., Bentley, G., 1953. Anticholinesterase properties of tetrahydroaminacridine. Aust. J. exp. Biol. 31, 573-578.
35. Shaw, H., Bentley, G., 1949. Some aspects of the pharmacology of morphine with special reference to its antagonism by 5-aminoacridine and other chemically related compounds. Med. J. auts. 2, 868-875.
36. Solomon, P.R., Knapp, M.J., Gracon, S.J., Groccia, M., Pendlebury, W.W., 1996. Long-term tacrine treatment in patients with Alzheimer's disease. Lancet 348, 275-276.
37. Summers, W.K., Viesselman, J.O., Marsh, G.M., Candelora, K., 1981. Use of THA in treatment of Alzheimer-like dementia: pilot study in twelve patients. Biol. Psych. 26, 145-153.
38. Summers, W.K., Majowski, L.V., Marsh, G.M., Tachiki, K., Kling, A., 1986 Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. New England J. of Med. 315, 1241-1245.
39. Thai, L., Fuld, P.A., Masur, D.M., Sharpless, N.S., 1983. Oral physostigmine and lecithin improve memory in Alzheimer disease. Ann. Neurol. 13, 491-496.
40. Wilcock, G.K., Scott, M., Pearsall, T., 1994. Long-term use of tacrine, Lancet 343, 294.
41. Wilkinson, D., 1997. Galanthamine hydrobromide - Results of a group study. Eight Congress Int. Psychoger. (Jerusalem) Abstr. p. 70.